Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).
Publication/Presentation Date
5-2014
Volume
32
Issue
15
Published In/Presented At
DOI: 10.1200/jco.2014.32.15_suppl.e16061
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS